Compare Revvity Inc (RVTY) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Tripadvisor Inc Common Stock — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B). The key difference: Revvity Inc is far larger — about 16.8× Tripadvisor Inc Common Stock's market cap, and Revvity Inc pays a 0.18% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| RVTY | TRIP | |
|---|---|---|
Market Cap | $16.98B | $1.01B |
Volume | 1,456,900 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $16.72 |
52-Week Low | $82.26 | $8.04 |
Typical Hold Time | 12 Days | 57 Days |
Enterprise Value | $19.30B | $1.06B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
TripAdvisor (TRIP) trades at $8.96, up 3.82% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with strong gross margins (92.11%) but thin net income (0.27%), while valuation appears reasonable with P/S of 0.57. Recent news highlights institutional buying interest but also concerns about AI competition eroding the core business model.
The outlook remains cautious with Wall Street maintaining a hold-heavy consensus (62.5%) despite a $13.58 price target suggesting 52% upside. Key risks include persistent earnings underperformance, competitive pressure from AI travel tools, and declining cash flow trends. The investment case hinges on Viator's performance and successful execution amid travel industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
